Investigational New Drug (IND) Applications

For conducting clinical trials with Investigational Drugs or Drugs that are not approved for intended use, the sponsor must submit an Investigational New Drug Application (IND) to the US FDA and obtain the Agency acceptance before the drug is transported or distributed across the US for use in the clinical program. In case, if the sponsor fails to submit adequate information in the IND Application to assure product quality, safety and scientific evidence on proposed efficacy profile, the US FDA may issue a Clinical Hold (full clinical hold or partial clinical hold), restricting sponsors to move forward unless issues are addressed. 

Freyr assists sponsors with end-to-end Regulatory support for IND programs, starting from pre-IND meetings to Regulatory compliance and management of late phase submissions when the IND goes effective.  

Freyr Expertise

  • Gap analysis of IND developmental data against current federal Regulatory requirements for conducting human clinical trials; and to identify potential clinical hold issues (Critical & Major)
  • Regulatory support for Pre-IND meetings and other agency communications (Type A, Type B, Type C and Biosimilar Biological Product Development (BPD) meetings)
  • Request for ODD (Orphan Drug Designation) or for expedited review program designations
  • Strategic support in identifying the optimal Regulatory approach for an intended clinical program(s) and IND submission
  • Expert advice on Regulatory mitigation plans for identified data deficiencies and clinical hold issues during the IND process
  • Extensive understanding on NDA/BLA submission requirements and data correlations from IND to future marketing authorization applications
  • Publishing and eCTD submission of initial INDs and subsequent submissions (IND annual reports, amendments, etc.)
  • Regulatory response strategy, preparation and on-time response submission to the US FDA Queries/information requests
  • Consulting support for IND inactivation or IND re-activation
  • US agent services
  • IND submission templates in eCTD format
  • Preparation, technical review and submission of CMC, nonclinical & clinical packages for initial IND submission; IND amendments, safety reporting, IND annual reports submission in eCTD format for different types of medicinal products (New chemical entities, vaccines, biosimilars and other biological products like tissue and gene therapy products, etc.)

Latest Resources

  • Blogs

    ANVISA Becomes a Member of PIC/s Committee

    ANVISA Becomes a Member of PIC/s Committee

    Read More
  • White Papers

    Factors that May Cause FDA to Refuse to Receive (RTR) an ANDA

    Factors that May Cause FDA to Refuse to Receive (RTR) an ANDA

    Read More
  • Webinars

    Strategic Regulatory Partnerships How to Evaluate & Engage with a Regulatory Partner

    Strategic Regulatory Partnerships How to Evaluate & Engage with a Regulatory Partner?

    Read More

What Our Clients Say?

background
Quick Inquiry
x